Fibroblast growth factor 23 and bone mineralisation.
Fibroblast growth factor 23 and bone mineralisation.
复制标题
成纤维细胞生长因子 23 和骨矿化
DOI：
10.1038/ijos.2015.1
复制
发表时间：
2015-03-23
影响因子：
14.9
通讯作者：
Yuan Q
中科院分区：
文献类型：
--
作者：
Guo YC;Yuan Q
成纤维细胞生长因子23 （Fibroblast growth factor 23, FGF23）是骨内主要由骨细胞和成骨细胞分泌的一种激素。FGF23在矿物离子稳态中的关键作用首先在人类遗传和获得性佝偻病中被发现，并在动物模型中得到进一步表征。最近的研究表明，FGF23水平在慢性肾脏疾病（CKD）的早期阶段显著升高，并可能在这些患者的矿物质离子紊乱和骨代谢中发挥关键作用。我们最近的出版物也表明，FGF23及其辅助因子Klotho可能在直接调节骨矿化中发挥独立作用，而不是产生系统效应。在这篇综述中，我们将讨论FGF23在骨矿化和ckd相关骨疾病的病理生理中的新作用。
Fibroblast growth factor 23 (FGF23) is a hormone that is mainly secreted by osteocytes and osteoblasts in bone. The critical role of FGF23 in mineral ion homeostasis was first identified in human genetic and acquired rachitic diseases and has been further characterised in animal models. Recent studies have revealed that the levels of FGF23 increase significantly at the very early stages of chronic kidney disease (CKD) and may play a critical role in mineral ion disorders and bone metabolism in these patients. Our recent publications have also shown that FGF23 and its cofactor, Klotho, may play an independent role in directly regulating bone mineralisation instead of producing a systematic effect. In this review, we will discuss the new role of FGF23 in bone mineralisation and the pathophysiology of CKD-related bone disorders.